Three-phase treatment offers patients with HSV infections an alternative to perpetual antiviral management ROATAN, BAY ...
The new oral therapy demonstrates superior lesion healing for complex patients who have few current treatment options.
Researchers at the University of Jyväskylä (Finland), in cooperation with national and international research groups, have ...
Pritelivir met its primary endpoint of superior lesion healing, achieving a 62.7% lesion healing rate compared to 34.0% with ...
Clinical Trials Arena on MSN
AiCuris reports positive Phase III pritelivir results for HSV patients
The trial enrolled and treated 101 immunocompromised patients with refractory or resistant HSV infection.
The incidence of neonatal herpes simplex virus (HSV) infections in the UK and Ireland increased dramatically over 15 years, and outcomes remained poor, with mortality and long-term neurologic ...
A phase 3 trial finds pritelivir significantly improves cure rates for immunocompromised individuals with refractory HSV infections.
Herpes is one of the most common viral infections in the world, yet it remains widely misunderstood. Caused by the herpes ...
– ABI-5366 is currently being evaluated in ongoing Phase 1b clinical trial with interim proof-of-concept data expected in fall 2025 – SOUTH SAN FRANCISCO, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results